Delving into the Latest Updates on MK-6183 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Cubist Pharmaceuticals LLC

Active Organization-

Inactive Organization

Cubist Pharmaceuticals LLC

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to characterize the effect of renal function on the plasma, urine, and dialysate pharmacokinetic profile of MK-6183 (CB-238,618) in humans. The study will also assess the safety profile and tolerability of MK-6183 in healthy participants, participants with varying degrees of renal impairment (RI), or participants with end-stage renal disease (ESRD) requiring hemodialysis (HD), based on estimated glomerular filtration rate (eGFR).

Start Date11 Dec 2014

Sponsor / Collaborator

Cubist Pharmaceuticals LLC

100 Clinical Results associated with MK-6183

Login to view more data

100 Translational Medicine associated with MK-6183

Login to view more data

100 Patents (Medical) associated with MK-6183

Login to view more data

100 Deals associated with MK-6183

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02341599 (CTgov)	Phase 1	Renal Insufficiency \| Kidney Failure, Chronic	40	MK-6183 (Group A: Healthy)	hlpldhsvlv(algvguwemm) = icspxatuwt nqqtdsibzi (oxakulwmcm, 8.49) View more	-	18 Feb 2019
				MK-6183 (Group B: Mild RI)	hlpldhsvlv(algvguwemm) = hvxzqcujro nqqtdsibzi (oxakulwmcm, 23.20) View more